` BVS (Bioventus Inc) vs S&P 500 Comparison - Alpha Spread

BVS
vs
S&P 500

Over the past 12 months, BVS has significantly outperformed S&P 500, delivering a return of 96% compared to the S&P 500's 24% growth.

Stocks Performance
BVS vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BVS vs S&P 500

Loading
BVS
S&P 500
Difference

Performance By Year
BVS vs S&P 500

Loading
BVS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Bioventus Inc vs Peers

S&P 500
BVS
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Bioventus Inc
Glance View

Market Cap
777.2m USD
Industry
Health Care

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.

BVS Intrinsic Value
11.53 USD
Undervaluation 17%
Intrinsic Value
Price
B
Back to Top